Why Terumo is on investors’ radar today

Terumo (TSE:4543) has attracted attention after a 20.1% gain over the past week, adding to shorter term momentum following a 6.2% move over the past month and 17.3% over the past 3 months.

See our latest analysis for Terumo.

That recent surge sits against a more muted picture, with a 1 year total shareholder return that is down 11.94%, while the 3 year and 5 year total shareholder returns are 15.47% and 18.67%. This suggests momentum has picked up only recently.

If Terumo’s move has you watching healthcare more closely, it could be a good moment to scan other medical technology opportunities using our healthcare focused screener, starting with 8 healthcare AI stocks.

With Terumo shares recently climbing yet still trading at what some models flag as roughly a 25% discount to estimated intrinsic value, investors may be wondering whether there is real upside or whether the market is already pricing in future growth.

Most Popular Narrative: 18.4% Undervalued

Terumo’s most followed narrative pegs fair value at ¥2,871.54, compared with a last close of ¥2,342.5. This frames a sizeable valuation gap that hinges on earnings power and margins.

Broad-based deployment and ramp-up of high-margin consumables, such as Rika in Global Blood Solutions, are driving improved production efficiency and a more favorable revenue mix; this recurring consumable revenue base is likely to further enhance profitability and cash flow. Ongoing investment in and success of minimally invasive and specialized intervention systems are leading to higher patient volumes and improved market share, particularly in high-growth areas like oncology and peripheral intervention, giving Terumo a sustainable driver for above-market revenue and earnings expansion.

Read the complete narrative.

Want to see what sits behind that cash flow story and higher margin view? The narrative leans heavily on revenue mix, recurring consumables, and future profitability assumptions.

Result: Fair Value of ¥2,871.54 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this depends on tariffs being passed through and pricing remaining stable, while any slowdown in China or weaker procedure volumes could quickly challenge that positive margin outlook.

Find out about the key risks to this Terumo narrative.

Another way to look at Terumo’s valuation

While the SWS DCF model points to Terumo trading at roughly a 25% discount to an estimated future cash flow value of ¥3,142.82, the current P/E of 25.4x is higher than the JP Medical Equipment industry at 14.7x and the peer average of 21.6x, yet sits below a fair ratio of 27.4x. That mix of discount on cash flows but premium on earnings leaves an important question: which signal do you trust more?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With the mixed signals on valuation and sentiment in mind, now is a good time to look through the numbers yourself and stress test the assumptions behind them. To see what the market currently views as the key positives, start with the 4 key rewards.

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your goals better. Use the screener to widen your field and compare options.

• Spot potential value opportunities early by checking companies that currently screen as 17 high quality undervalued stocks.
• Strengthen your focus on financial resilience with the solid balance sheet and fundamentals stocks screener (39 results).
• Prioritise income potential by reviewing stocks in the 45 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.